Research & Development
Innovation is in our DNA
Investment in R&D is an important driver for CSL's future growth. New and exciting opportunities allow us to address previously unmet patient needs and these continue to drive us every day.
In addition, CSL continues to build on its capabilities across the R&D value chain, from discovery research to pharmacovigilance to its currently marketed therapies. Such proficiency is critical as R&D builds the novel and diverse pipeline of the future.
We continue to make a balanced investment in the lifecycle management and market development of existing products that bring short to mid-term commercial benefits, and we make strategic investments in longer-term, higher risk and high opportunity new product development activities.
-
US $1.2 billion
was invested in R&D in 2022/23
-
US $5.1 billion
in R&D investments in the last 5 years
-
>2,000
research & development employees
Product pipeline
CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people's lives depend on it, CSL's R&D fuels the company's sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma protein technology, recombinant protein technology, cell and gene therapy technology and vaccines technology to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in six therapeutic areas: Immunology, haematology, respiratory, cardiovascular and metabolic, nephrology, and transplant and vaccines. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.